News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

How Rexis Biotech Aims To Become The Nvidia Of The Consumer Products Industry

Rexis Biotech

By Meg Flippin, Benzinga Click here to learn more about Rexis Systems’ crowdfunding raise, and how to invest Cannabis is going mainstream as more states legalize the leafy herb. That's spawning a multi-billion-dollar market for CBD and THC products, with manufacturers putting it in everything from candy to drinks. The cannabis-infused beverage category in particular is growing in popularity as people look for healthier ways to get a buzz. Last year, the cannabis drink market was valued at $0.4 billion. By 2032, it is projected to reach $8.3 billion at a 37.7% CAGR over 2023-2032. These drinks promise to give consumers a smoother, gentler taste with few calories and zero hangover in the morning. Rexis Biotech Inc., the biotech out of Delaware, is taking the cannabis-infused beverage market to the next level with its proprietary Fused Polymorph Nano Fiber Technology™ that enhances the benefits and effects of cannabis in drinks. The current cannabis-infused drinks on the market do provide a new experience to consumers, but there are some limitations. For starters, the body can’t efficiently absorb most plant-based ingredients like CBD, THC and caffeine. As a result, consumers typically only receive 10% or less of the ingredient in their system. It also takes longer to absorb into the bloodstream, usually 45 to 90 minutes, when using oil-based infusions. These tend to give more of an edible high, as they are processed during first-pass digestion, versus the smoking high that using nanotechnology is supposed to create. Up until now, nanoemulsions have been the go-to solution to solve for faster onset, but emulsions tend to be unstable, easily losing 30% efficacy within the first three months. On top of that, they often leave a bitter or oily aftertaste in your mouth. Rexis Enhances The Benefits Rexis Biotech reports that its proprietary drug delivery platform eliminates those undesirable aspects of nanoemulsions, allowing them to create a lineup of Hemp Delta-9 THC-infused beverages that both taste amazing and enhance the consumer experience. Squared, the first beverage out of the gate for Rexis, is a lineup of better-for-you-sodas that are both delicious and nutritious. Available in a variety of flavors from their Classic Orange Pop that tastes exactly like an Orange Crush to their High Spirits Awards-winning Sparkling Grapefruit, these cannabis-infused beverages onset in about 10-15 minutes and provide a reliable effect that’s closer to the dosage on the can. Rexis says it is able to achieve that thanks to its fast-acting nano fiber technology which enables the drink to quickly absorb through the buccal membranes in the mouth versus having to go through first-pass digestion like traditional edibles. This allows the body to absorb and process the Hemp Delta-9 THC faster and more effectively. Squared beverages are also formulated to offset in about an hour – a key differentiator. It puts consumers in the driver’s seat regarding how much and how long they want to feel the effects. Squared Is Just The Beginning Rexis is demonstrating its nanotechnology with the launch of Squared, but its vision is much bigger. It wants to share its technology, aiming to be the Nvidia Corp. (NASDAQ: NVDA) or Intel Corp. (NASDAQ: INTC) of the consumer products industry. It envisions a world where brands license Rexis’s nanotechnology to enhance everything from drinks to food. Its partnership with 3Chi, Inc., one of the world’s largest hemp-derived consumer packaged goods manufacturers and retailers, underscores how it’s making that ambition a reality. Functional foods and beverages “Powered by Rexis” will be sold via their national distribution network, Wicked Smart Food Company, and they expect it to drive revenues of $24.6 million over the next three years. “Rexis separates itself from the competition with its technology. Their Fused Polymorph Nano Fiber is several steps above anything else that's in the marketplace right now. The quality of product that we have gotten from them is unsurpassed,” Justin Journay, 3Chi CEO, said when the deal was announced in July. The cannabis-infused beverage market seems to be taking off, and Rexis wants to be a leader. As more states legalize it and consumers clamor for healthier and tastier alternatives, Rexis is betting its proprietary nanotechnology will become the engine that drives these beverages like Intel’s chips power PCs. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

October 31, 2023 09:15 AM Eastern Daylight Time

Article thumbnail News Release

Groundwork BioAg Supercharges Agricultural Carbon Sequestration

Groundwork BioAg

Groundwork BioAg ® announced today the global launch of the Rootella Carbon ™ program, based on mycorrhizal carbon - a frontier technology that leverages mycorrhizal fungi as a nature-based solution for carbon dioxide removal. Rootella Carbon harnesses the power of Rootella® – highly effective mycorrhizal inoculants that are proven to sequester significant amounts of carbon in cropland (1-4 tCO2eq/acre annually). This innovative, Verra-certified program represents a transformative approach to carbon sequestration for conventional and regenerative farmers alike. “Since our inception, we have known that mycorrhiza – the Queen of Biologicals™ – offers a compelling agricultural solution to mitigate climate change,” said Dr. Yossi Koffman, co-founder and CEO of Groundwork BioAg. “Rootella Carbon delivers on that vision by paving the way to a gigaton of CO2 sequestration in the next decade.” Rootella has been applied on over 4.5 million acres in 17 countries. Rootella Carbon Enrollment Unlocks New Value Carbon credit programs have been touted as a new revenue source for farmers, but adoption has been slow thus far due to high costs and practice change requirements. In a recent survey of top producers in the United States, 63% of respondents said they would enroll in a carbon program if a product like Rootella unlocks additional revenue and fits easily into existing farming practices. Simultaneously, carbon buyers are fueling demand for premium, verifiable credits to meet net-zero pledges responsibly and sustainably. This year, a select group of corn, soybean, alfalfa, and cotton farmers across eight states enrolled acres in Rootella Carbon, the first mycorrhizal carbon project in the world. “Clearly soil biology is the new frontier and will be for the next 10 years,” said Sledge Taylor, who farms corn, soybean and cotton on a multi-generational farm in Mississippi and enrolled in Rootella Carbon. "I invest in my soil; it is a true asset." Rootella Carbon Program Ushers in a New Asset Class • Enables Adoption by Conventional and Regenerative Farmers: Rootella Carbon provides growers the additionality, or practice change, needed for carbon credit eligibility, regardless of current cultivation practices. • Delivers Carbon Permanence: Mycorrhizal fungi are carbon’s main pathway into the soil. Up to 20% of plant photosynthate is passed to mycorrhizae, creating a positive net flux of carbon into the soil. Mycorrhizae aggregate soil particles to form stable and recalcitrant carbon-based molecules that persist in the soil for millennia. • Boasts Impressive Co-Benefits: Groundwork BioAg was the first to crack the code on mass production of mycorrhiza for mainstream agriculture. By joining the Rootella Carbon program, farmers can leverage the co-benefits of Rootella products, including increased yields, fertilizer savings, and stress tolerance, while earning carbon credits. • Generates Premium Carbon Credits: Rootella Carbon farmers expect to sequester 1-4 tCO2eq per acre per year—an unprecedented carbon sequestration rate. Carbon buyers gain access to high-integrity, high-volume, Verra-certified carbon credits. Enrollment in Rootella Carbon is currently open to farms with a minimum of 250 acres, at https://www.groundworkbioag.com/rootella-carbon About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg’s unique and proprietary manufacturing process was the first to solve challenges inherent in high-volume, supremely concentrated mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

October 31, 2023 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

Evgen Pharma "delighted" with cash position after promising first half

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones and new CFO Toni Hanninen speak to Thomas Warner from Proactive after the clinical stage drug development company announced its interim results for the six months to 31 September 2023. Dr Jones gives an overview of how Evgen has been performing on the operational side, highlighting clinical progress, the successful receipt of some new grant funding as well as changes to the board and to the executive team with the hiring of Toni Hanninen in late summer. Hanninen gives an overview of how Evgen performed financial during the reporting period, noting that there were no nasty surprises during the six months and that the company's cash runway of £3.7mln currently runs to the end of 2024. He goes on to say that he is "very very delighted" with the length of the runway given the financial challenges many of Evgen's peers are currently facing. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 31, 2023 06:43 AM Eastern Daylight Time

Video
Article thumbnail News Release

Medicus Pharma CEO rings opening bell at the Toronto Stock Exchange

Medicus Pharma

Medicus Pharma executive chairman and CEO Dr Raza Bokhari joined Steve Darling from Proactive fresh from ringing the opening bell at the Toronto Stock Exchange. This after the company recently listed its common shares on the TSX Venture exchange under the ticker MDCX. Medicus Pharma is dedicated to accelerating novel life sciences and biotechnology companies by advancing them through FDA-approved clinical trials. The company specializes in de-risking clinical-stage assets through clinical development and eventual commercialization. Medicus Pharma has a subsidiary called Skinject, which is focused on commercializing a novel, non-invasive treatment for basal cell and squamous cell skin cancer. Skinject employs a patented dissolvable microneedle patch to deliver a chemotherapeutic agent that targets and eradicates tumor cells effectively. The company recently welcomed Dr Huma Qamar as its chief scientific officer and head of R&D Program. Dr Qamar brings a wealth of experience in the clinical research field, having worked with prestigious institutions such as Yale University, Harvard University, and the University of Pennsylvania. Medicus Pharma's listing on the TSX Venture Exchange represents a significant step forward for the company as it continues its mission to advance innovative therapies and treatments in the field of life sciences and biotechnology. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:31 PM Eastern Daylight Time

Video
Article thumbnail News Release

Marizyme Inc CEO releases corporate update including details of key progress on DuraGraft

Marizyme Inc

Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for its groundbreaking product, DuraGraft. DuraGraft is a first-in-class vascular conduit solution that has received FDA clearance, marking a significant milestone for Marizyme. This innovative product is specifically indicated for use in adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries. Its primary purpose is to facilitate the flushing and storage of saphenous vein grafts employed in CABG procedures, offering a cutting-edge solution to enhance patient outcomes in cardiac surgery. One notable aspect of Marizyme's progress is the growing acceptance of DuraGraft in both Europe and Asia. The company has achieved impressive sales figures, with a total of 1,131 DuraGraft kits shipped so far this year. This is a remarkable increase compared to the 485 DuraGraft kits shipped in the previous year, underscoring the product's traction and demand in the international market. In summary, Marizyme, under the leadership of CEO David Barthel, is making significant strides in the medical industry. The FDA approval of DuraGraft and its increasing adoption in international markets signify the company's commitment to advancing medical technologies that improve patient outcomes. As Marizyme continues to expand its reach and forge new partnerships, it is poised for continued growth and success in the years ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:23 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioHarvest Sciences closes first tranche of financing bringing in C$11.78M to Treasury

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share some exciting developments. The company has achieved a major milestone by successfully closing the first tranche of its financing, raising nearly C$12 million, even in the face of challenging market conditions. This accomplishment underscores the significant investor confidence in BioHarvest's strategic vision and the strength of its management team. The capital raised through this financing round will play a pivotal role in advancing several key initiatives within BioHarvest Sciences. One of the notable areas of focus is new product development and expansion. BioHarvest has ambitious plans to expand its product range, moving from a single SKU to ten SKUs spanning five different categories. Leveraging its advanced scientific capabilities, proven efficacy, and exceptional taste, the company is poised to make a significant impact in these markets. The eagerly awaited flagship product, a revolutionary coffee offering, is slated to disrupt the market starting in December. Geographical expansion is another crucial aspect of BioHarvest's growth strategy. With recent approval from Health Canada, the company is gearing up to enter the Canadian market, further extending its global footprint. Additionally, BioHarvest is accelerating clinical trials across various domains, positioning itself for substantial growth over the next 12 to 24 months. These clinical trials will not only underscore the efficacy of their products but also enhance their credibility and market presence. Despite the challenges posed by the current market conditions, BioHarvest remains unwavering in its commitment to the safety of its employees and the consistent delivery of high-quality products. The company's focus for the remainder of 2023 includes robust marketing initiatives and the highly anticipated launch of its innovative coffee product, aimed at revitalizing the stagnant decaffeinated coffee market. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:18 PM Eastern Daylight Time

Video
Article thumbnail News Release

1606 Corp announces cutting-edge AI-driven ChatCBDW will launch on Tuesday

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to unveil some thrilling news: the impending launch of its cutting-edge AI chatbot, ChatCBDW. With ChatCBDW currently undergoing final testing phases, the countdown to its official launch is well underway. Lambrecht eagerly shared with Proactive the multifaceted capabilities that ChatCBDW is poised to bring to its users. This AI chatbot has been meticulously designed to offer a diverse range of user-centric features that go beyond the ordinary. Among its standout attributes are its ability to respond to user queries and provide comprehensive education on all aspects of CBD. But ChatCBDW doesn't stop there; it takes personalization to the next level by offering tailored product recommendations to users and engaging in conversations that closely mimic human interaction. This innovation empowers customers to make well-informed choices, explore a wide array of CBD products, and promises an unparalleled shopping experience in the CBD space. At the core of ChatCBDW's prowess is its seamless integration with Microsoft Azure, a platform renowned for its scalability, unwavering reliability, and cutting-edge AI functionalities. This integration ensures that ChatCBDW can operate impeccably, even during peak demand periods, guaranteeing users a consistently responsive and seamless experience throughout their interaction with the chatbot. Notably, 1606 Corp proudly retains 100% ownership of ChatCBDW's intellectual property, demonstrating its commitment to maintaining control over this groundbreaking technology. This ownership provides the company with the flexibility to continually enhance and adapt ChatCBDW to meet the ever-evolving needs of its users and partners across various industries. It signifies 1606 Corp's dedication to staying at the forefront of innovation in the field of AI-driven customer engagement and CBD product discovery. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 02:16 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial

BioVie Inc

BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to share news the company will be presenting its blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The presentation will be presented at the upcoming 16th Clinical Trials on Alzheimer's Disease in Boston. Do told Proactive the company has monitored blinded data as they become available throughout the trial to assess patient safety and support timely data entry into the official statistical analysis database. Interim blinded data was previously presented at other scientific congresses to provide a glimpse of the characteristics of the enrolled subjects at the start of the trial. The most surprising revelation was the reduction in amyloid burden. NE3107, designed to block TNF alpha, demonstrated a substantial reduction in amyloid buildup within just six months of treatment. More than a third of initially amyloid-positive patients became amyloid-negative, a highly unexpected outcome. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

October 30, 2023 01:00 PM Eastern Daylight Time

Video
Article thumbnail News Release

Majority of medical and nursing students planning careers outside patient care as fears of burnout and staff shortages leave them worried about the future

Elsevier

Elsevier Health’s first global “Clinician of the Future 2023: Education Edition” highlights students’ deep concerns about balancing their commitment to patient care with their own well-being. The report also identifies key insights into students’ excitement and fears towards technology and AI in healthcare education Today, Elsevier Health, a global leader in evidence-based clinical practice content, research publishing and information analytics, releases its Clinician of the Future 2023: Education Edition, providing unparalleled insights into the experiences of medical and nursing students and the consequences for the NHS and educators in the UK. The report reveals how the challenges of being a frontline health professional today are impacting the longer-term career decisions of students, highlighting increasingly challenging times ahead for an already overburdened healthcare system. Although almost 9 out of 10 medical and nursing students in the UK feel devoted to improving patients’ lives, findings reveal that 58% already see their current studies as a steppingstone towards a broader career in healthcare that will not involve directly caring for patients. The Clinician of the Future 2023: Education Edition presents a worrying snapshot of the pressures that medical and nursing students feel today alongside the impending alarm they have for life in clinical practice: 20% of medical and nursing students in the UK are considering quitting their undergraduate studies 57% of medical and nursing students in the UK report they are worried about their mental well-being 64% of medical and nursing students in the UK believe they will suffer from clinician burnout 75% of medical and nursing students in the UK are concerned about healthcare staff shortages and the impact this would have on them in their future role Anjola Awe, a third-year medical student at King’s College London, said: “I have always known that I wanted to be a doctor; I’ve dedicated my life to getting to this stage. Honestly, the findings and themes in the report are not at all surprising to me or my peers; we know only too well the reality of what being a frontline healthcare professional means today. We need to be vocal about the pressure we are under, the state of our mental health, and the volume of our academic workload.” As of June this year, there were more than 125,000 vacancies in secondary care in England, and over 10% of all nursing posts remain unfilled. 1 Despite the NHS treating more patients than before the pandemic, the waiting list for NHS treatment currently stands at a record 7.75 million. 2 Against this backdrop, it is unsurprising that medical and nursing students in the UK are concerned about the challenges they will face in the future. Dr Philip Xiu, a general practitioner and educational lead who supports medical students and junior doctors in Leeds, West Yorkshire, said: “As an educator, I see daily how vital it is we address students’ well-being concerns. Doubling enrolment won’t resolve looming workforce shortages if issues impeding student wellness go unresolved. We must equip them with critical thinking to aid sound clinical decisions, and partnership skills to involve patients meaningfully in care. By listening and responding to students’ needs, we can graduate resilient, empowered clinicians ready to elevate healthcare.” The Clinician of the Future 2023: Education Edition also identifies key insights into both the excitement and reservation towards technology and generative AI student curriculum. In the UK, 53% of medical and nursing students say they are excited at the potential of AI; however, 54% report they are worried about its use to support education. Furthermore, 74% admit to feeling overwhelmed by the amount of information they are expected to retain, with 44% now using generative AI, such as ChatGPT and Bard. Jan Herzhoff, President of Elsevier Health, said: “It’s clear that healthcare across the globe is facing unprecedented pressures, and that the next generation of medical and nursing students are anxious about their future. Whether through the use of technology or engaging learning resources, we must support students with new and innovative approaches to enable them to achieve their potential. However, the issues raised in this report can’t be tackled in isolation; it is essential that the whole healthcare community comes together to ensure a sustainable pipeline of healthcare professionals.” The Clinician of the Future 2023: Education Edition is the third edition published as part of Elsevier Health’s Clinician of the Future program, serving as the global health ecosystem’s leading pulse on the changes and challenges facing the doctors and nurses of today and tomorrow. For the full Clinician of the Future 2023: Education Edition, which includes robust data on global student attitudes toward health education, the future of healthcare, as well as the perspectives of instructors and more, click here. ### References: The British Medical Association. NHS medical staffing data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/workforce/nhs-medical-staffing-data-analysis (Accessed: 18 October 2023). The British Medical Association. NHS backlog data analysis, The British Medical Association. Available at: https://www.bma.org.uk/advice-and-support/nhs-delivery-and-workforce/pressures/nhs-backlog-data-analysis (Accessed: 18 October 2023). Notes to editors: Research Methodology The Clinician of the Future 2023: Education Edition presents the results of a global survey of 2,212 students and two roundtable sessions with key opinion leaders in faculty in the US and UK. The aim is to gain a deep understanding of students’ experiences today and their expectations of the future in healthcare, as well as the perspectives of those instructing them. Elsevier Health’s commitments In addition to the Clinician of the Future 2023: Education Edition, we are committed to the following: Community Advisor Programmes of Osmosis: Providing elements of mentorship and connection to clinician communities Campus visits and feedback from students: Listening and learning through student feedback on how they are approaching their education challenges Year of the Zebra: An initiative to increase awareness of rare diseases and the benefits of patient care Hackathons: Providing clinical challenges for students in North America to advance their clinical education. Hosting webinars on resilience and depression in healthcare, as well as developing podcast episodes relevant to healthcare challenges Continued internships for medical and nursing students Supporting scholarships for minority students through the Elsevier Foundation About Elsevier Health For more than 140 years, Elsevier has supported the work of researchers and healthcare professionals by providing current, evidence-based information, that can help empower students and clinicians to provide the best healthcare possible. Growing from our roots, Elsevier Health applies innovation, facilitates insights, and helps drive more informed decision-making for our customers across global health. We support health providers by providing accessible, trusted evidence-based information to take on the infodemic; prepare more future health professionals with effective tools and resources; provide insights that help clinicians improve patient outcomes; deliver healthcare that is truly inclusive; and supports a more personalized and localized healthcare experience. Diversity and inclusion are the foundation of our innovation, and our teams are committed to creating education and practice solutions that reflect the diversity of our world. Elsevier is helping lay the groundwork for more equitable healthcare worldwide; We bring the same rigor to our digital information solutions as we do to our publishing, allowing us to offer knowledge and valuable analytics that help our users make breakthroughs and drive progress for the benefit of every patient. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, academic leaders, funders, R&D-intensive corporations, doctors, and nurses. Elsevier employs 9,000 people worldwide, including over 2,500 technologists. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on over 2,800 journals, including The Lancet and Cell; 46,000+ eBook titles; and iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details Dan DiPietro-James Global Media Relations Director dan.james@elsevier.com Chris West Senior Manager, Global Communications c.west1@elsevier.com Company Website https://www.elsevier.com/

October 30, 2023 03:45 AM Eastern Daylight Time

1 ... 8182838485 ... 309